High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.

Antimonials are still being used for visceral leishmaniasis (VL) treatment among HIV co-infected patients in East-Africa due to the shortage of alternative safer drugs like liposomal amphotericin B. Besides tolerability, emergence of resistance to antimonials is a major concern.This study was aimed...

Full description

Bibliographic Details
Main Authors: Ermias Diro, Lutgarde Lynen, Rezika Mohammed, Marleen Boelaert, Asrat Hailu, Johan van Griensven
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-05-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC4031116?pdf=render
_version_ 1817997513037185024
author Ermias Diro
Lutgarde Lynen
Rezika Mohammed
Marleen Boelaert
Asrat Hailu
Johan van Griensven
author_facet Ermias Diro
Lutgarde Lynen
Rezika Mohammed
Marleen Boelaert
Asrat Hailu
Johan van Griensven
author_sort Ermias Diro
collection DOAJ
description Antimonials are still being used for visceral leishmaniasis (VL) treatment among HIV co-infected patients in East-Africa due to the shortage of alternative safer drugs like liposomal amphotericin B. Besides tolerability, emergence of resistance to antimonials is a major concern.This study was aimed at assessing the clinical outcome of VL-HIV co-infected patients when treated with sodium stibogluconate (SSG).Retrospective patient record analysis of VL-HIV co-infected patients treated at a clinical trial site in north-west Ethiopia was done. Patients with parasitologically confirmed VL and HIV co-infection treated with SSG were included. The dose of SSG used was 20 mg Sb5 (pentavalent antimony)/kg and maximum of 850 mg Sb5 for 30 days. The clinical outcomes were defined based on the tissue aspiration results as cure or failure, and additionally the safety and mortality rates were computed.The study included 57 patients treated with SSG and by the end of treatment only 43.9% of patients were cured. The parasitological treatment failure and the case fatality rate were 31.6% and 14.0% respectively. SSG was discontinued temporarily or permanently for 12 (21.1%) cases due to safety issues. High baseline parasite load (graded more than 4+) was significantly associated with treatment failure (odds ratio = 8.9, 95% confidence interval = .5-51.7).SSG is not only unsafe, but also has low effectiveness for VL-HIV patients. Safe and effective alternative medications are very urgently needed. Drug sensitivity surveillance should be introduced in the region.
first_indexed 2024-04-14T02:38:09Z
format Article
id doaj.art-bffc41179ade4087abbe08742b33917d
institution Directory Open Access Journal
issn 1935-2727
1935-2735
language English
last_indexed 2024-04-14T02:38:09Z
publishDate 2014-05-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj.art-bffc41179ade4087abbe08742b33917d2022-12-22T02:17:16ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352014-05-0185e287510.1371/journal.pntd.0002875High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.Ermias DiroLutgarde LynenRezika MohammedMarleen BoelaertAsrat HailuJohan van GriensvenAntimonials are still being used for visceral leishmaniasis (VL) treatment among HIV co-infected patients in East-Africa due to the shortage of alternative safer drugs like liposomal amphotericin B. Besides tolerability, emergence of resistance to antimonials is a major concern.This study was aimed at assessing the clinical outcome of VL-HIV co-infected patients when treated with sodium stibogluconate (SSG).Retrospective patient record analysis of VL-HIV co-infected patients treated at a clinical trial site in north-west Ethiopia was done. Patients with parasitologically confirmed VL and HIV co-infection treated with SSG were included. The dose of SSG used was 20 mg Sb5 (pentavalent antimony)/kg and maximum of 850 mg Sb5 for 30 days. The clinical outcomes were defined based on the tissue aspiration results as cure or failure, and additionally the safety and mortality rates were computed.The study included 57 patients treated with SSG and by the end of treatment only 43.9% of patients were cured. The parasitological treatment failure and the case fatality rate were 31.6% and 14.0% respectively. SSG was discontinued temporarily or permanently for 12 (21.1%) cases due to safety issues. High baseline parasite load (graded more than 4+) was significantly associated with treatment failure (odds ratio = 8.9, 95% confidence interval = .5-51.7).SSG is not only unsafe, but also has low effectiveness for VL-HIV patients. Safe and effective alternative medications are very urgently needed. Drug sensitivity surveillance should be introduced in the region.http://europepmc.org/articles/PMC4031116?pdf=render
spellingShingle Ermias Diro
Lutgarde Lynen
Rezika Mohammed
Marleen Boelaert
Asrat Hailu
Johan van Griensven
High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
PLoS Neglected Tropical Diseases
title High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
title_full High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
title_fullStr High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
title_full_unstemmed High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
title_short High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
title_sort high parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among hiv co infected adults in ethiopia
url http://europepmc.org/articles/PMC4031116?pdf=render
work_keys_str_mv AT ermiasdiro highparasitologicalfailurerateofvisceralleishmaniasistosodiumstibogluconateamonghivcoinfectedadultsinethiopia
AT lutgardelynen highparasitologicalfailurerateofvisceralleishmaniasistosodiumstibogluconateamonghivcoinfectedadultsinethiopia
AT rezikamohammed highparasitologicalfailurerateofvisceralleishmaniasistosodiumstibogluconateamonghivcoinfectedadultsinethiopia
AT marleenboelaert highparasitologicalfailurerateofvisceralleishmaniasistosodiumstibogluconateamonghivcoinfectedadultsinethiopia
AT asrathailu highparasitologicalfailurerateofvisceralleishmaniasistosodiumstibogluconateamonghivcoinfectedadultsinethiopia
AT johanvangriensven highparasitologicalfailurerateofvisceralleishmaniasistosodiumstibogluconateamonghivcoinfectedadultsinethiopia